Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Show detailsHide details
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Kala Bio, Inc.
A biopharmaceutical company developing treatments for eye diseases, best known for EYSUVIS, an eye drop approved to treat inflammation and pain after eye surgery. The company, founded in 2009 as Kala Pharmaceuticals and renamed Kala Bio, also developed Inveltys for ocular inflammation. Its name was inspired by the medical journal of the American Academy of Ophthalmology, which in early years was called "Kala" — a nod to the field it serves.
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8.01 Other Events · 9.01 Financial Statements and Exhibits
3.03 Material Modification to Rights of Security Holders · 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 8.01 Other Events · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 3.02 Unregistered Sales of Equity Securities · 7.01 Regulation FD Disclosure
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
1.01 Entry into a Material Definitive Agreement · 3.02 Unregistered Sales of Equity Securities · 5.01 Changes in Control of Registrant · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing